Robert Sandrock

About Robert Sandrock

Over 20 years of driving Drug Development innovation with leadership roles across R&D disciplines including OMICs, Biosimilars, Target Discovery and Validation and experience with Regulatory Marketing Applications. I have an established track record as a thought leader with a focus on implementing OMICs insights and industry leading technologies for progressing novel therapeutics from the bench to the clinic. My deep experience across large and small biotech companies has given me the opportunity to refine my soft skills to become a successful connector of people in challenging and high-pressure environments.

Experience

1. Clinical Omics Director

   Amgen

   May 2022 — Present · Thousand Oaks, CA, US

   Applying the use of omics (genomics, transcriptomics, proteomics, etc) insights to inform the development strategy of Amgen\'s novel therapeutics. By utilizing our internal capabilities and external partners, I seek to better understand patient segmentation and heterogeneity of response to therapy, resulting in optimal translation of research discoveries into meaningful therapies for patients. I work closely with asset teams to develop and operationalize strategies to deliver omics insights during the development life cycle and act as a key enabler in Amgen\'s move toward clinical development driven by precision medicine.

Education

• University of Arizona

  PhD, Plant Pathology, Molecular Genetics

  1991 — 1996

• Cornell University

  Post-Doctoral Research, Molecular Plant Pathology

  1996 — 1998

• The Ohio State University

  B.S., Molecular Genetics

  1985 — 1989

Skills

• Assay Development
• Biotechnology
• Genomics
• Molecular Biology
• Lifesciences
• Qpcr
• Biochemistry
• Genetics
• Cell Culture
• Bioinformatics
• Drug Discovery
• Dna
• Cell Biology
• Cell
• Protein Chemistry